Two historical developments last year will help US seniors satisfy their appetite for CBD in 2019. We tell you:
2018 was the year in which cannabidiol (CBD) was on everyone’s lips, thanks to the great media boom and the sudden and ubiquitous presence of a wide variety of beverages, lotions, and personal care products with CBD infusion. It was also the year that the “CBD gummies” reached number 3 in Google’s most popular search terms. I dare say, riskily, that the Baby Boomers did a significant part of those searches.
CBD, a non-intoxicating compound found in cannabis, is being touted as a natural remedy for chronic pain, insomnia, depression, and anxiety, among other conditions. And although research to test the therapeutic results of the CBD is still near, it is not surprising that adults over 50, who suffer most of these conditions, are behind one of the fastest growing market segments for CBD products.
Two historical developments last year will make it much easier for older adults to satisfy their appetite for the CBD in 2019.
In a historical reconsideration of Cannabis Classification 1, the FDA proved willing to recognize that a component of marijuana actually has a therapeutic value. Epidiolex from the GW Pharmaceuticals laboratory, was the first cannabis-based drug to be approved by the FDA, the CBD was rescued from exile in Classification 1, joining cough syrup and diarrhea remedies in the convenient main line of Classification 5.
With the availability of new strains of hemp created especially to produce a high CBD content, US farmers, processors and many others along the revenue stream are eager to produce and distribute most of this lucrative substance to the market. Rapid growth can accommodate. And as CBD sales in the United States are expected to reach 22 billion dollars by 2022, as projected by the cannabis market research company, Brightfield Group, the re-regulation of hemp in Congress is a good reason to celebrate for many.
The FDA, however, hastened to curb the anticipated hemp festival. FDA Commissioner Scott Gottlieb issued a statement just before Christmas declaring that, despite the new classification for hemp, any product containing cannabis or CBD is still subject to FDA regulations and is prohibited for interstate commerce. .
However, a visit to any naturist store or an online search will show that FDA warnings have been largely ineffective in stopping the flow of CBD products. To stay safe, manufacturers simply avoid making explicit statements of therapeutic benefits on the labels of their products. This can make older consumers dependent on the Internet and social media for guidance on how, or at what dose, a product can potentially benefit them. And because CBD products tend to be expensive, this becomes a costly proposition with unclear results, particularly for older adults who are less likely to pay for them.
With CBD products that currently reside in the gray area of regulation between dietary supplements and medications, there is a good reason for older consumers to be cautious. A recent study that evaluated the accuracy of the labeling information of CBD products purchased online, published in the Journal of the American Medical Association, found that only about 30% of the sampled products were accurately labeled with respect to the levels of CBD and THC that they contained. It was found that some had CBD levels so low that any potential clinical benefit was invalidated. Others had THC levels high enough to give the unsuspecting consumer a slight stir.
Recognizing the urgency of this challenge, FDA Commissioner Gottlieb will soon convene a public meeting to discuss the CBD with interested parties. What is certain is that, until the authorities can discover how to respond to the high demand for CBD products, consumers should experience on their own how to better evaluate and manage the products they find. For older adults, this can be an extremely daunting task. Meanwhile, it is clear that, by the beginning of 2019, the need for uniform standards for the manufacture, testing, labeling and dosing of CBD products is already an urgent public health problem.
Hello2019 | Recreational marijuana will be a reality
Legal access to recreational marijuana took more and more force in the world in countries such as Uruguay, the United States, and Canada. In Mexico, the possibility of accessing the plant for recreational purposes could become a reality at the beginning of 2020.
“Being the most optimistic, we will be able to approve recreational marijuana until the beginning of 2020, according to what we have seen,” said Lorena Beltrán, general director of Cannabisalud and Endonatura.
According to the founder of the Cannabis Industry Association in Mexico, in June 2017 the General Health Law for the importation of cannabis products was modified and came into force only in October of this year.
“In no country had a government seen the path of all sectors to the plant. It is the first time in the world that in the country will discuss all the regulations of the plant, “said Beltrán.
These are the steps to follow for the approval of recreational marijuana.
- At present, the initiative proposed by the secretary of governance, Olga Sánchez Cordero, is in the hands of several groups in Congress that are analyzing it before it passes to the Chamber of Senators.
- After passing this analysis, it will be voted in the Senate in February or March 2019.
- Once it is approved in the Senate, it passes to the Chamber of Deputies where it is voted and then the necessary modifications of the General Health Law will be made.
- Once the necessary modifications are made, the regulatory period is entered with the Secretary of Health, the Sagarpa, the Cofepris, and the agencies involved, which have 180 days to draw up a regulation based on this new law. For Lorena Beltran, this could happen until the beginning of 2020.
The initiative to legalize the sowing, production, and consumption of marijuana that Cordero presented is an important step for the country and represents a mixture of the existing regulation in Canada and Uruguay.
“I think we got the best of each one, although I think there are some things that could be tropicalized. The most important thing is that we are going to allow the cultivation, “said Lorena Beltrán.
The initiative specifies that each consumer can plant up to 20 plants and have access to 480 grams of the plant per year.
“Since 20 plants give more than 480 grams of marijuana, the rest can be sold for medical or industrial use,” said Lorena Beltran.
According to Lorena Beltrán, half of the people in the country still do not understand what marijuana represents and are generally against it.
“People distrust and do not understand the benefit of the plant because there is no such information available to people,” said Beltrán.
This problem, according to the directive, permeates even authorities in the country, as is the case of the Ministry of Economy that questioned the value of the permits granted in Mexico by Cofepris, due to the incorrect interpretation of the tariff fractions that are found in the Law of the General Taxes of Importation and Exportation in force and that prohibit the importation of some activities.
And according to the members of the newly created Association of the Cannabis Industry in Mexico, “although the General Directorate of Foreign Trade mentions in its office the eight tariff fractions, these are not applicable to our products because they specifically speak of Cannabis Indica, being that our products come from Cannabis (Cannabis Sativa) “.
For Lorena Beltrán the challenge is great because if the authorities are unaware of the issue, people are more uninformed.
“But neither is it worth to judge the people who are against it. We were all born in a prohibitionist era, in a time when marijuana was equal to or worse than cocaine, so changing that mentality is going to take time, “the board said.
The Mazatlan Post